The meeting featured international societies and the first Spanish language abstract session, enhancing global collaboration in sexual medicine. Instructional courses covered topics like androgens, ...

Lu-PSMA-I&T significantly extended rPFS in PSMA-positive mCRPC patients compared to hormone therapy in the ECLIPSE trial. The trial enrolled over 400 patients globally, with primary and secondary ...

Stone Clear provides a non-invasive option for managing post-lithotripsy kidney stone fragments, reducing complications and repeat procedures. Ultrasonic propulsion significantly extends time to ...

Disparities in BPH treatment reimbursement across Canada may affect the adoption of new technologies and influence treatment choices. Current reimbursement models may lead to potential misuse and ...

Clarity Pharmaceuticals and Nucleus RadioPharma collaborate to develop Cu-SAR-bisPSMA for mCRPC treatment in the SECuRE trial. The SECuRE trial's cohort 4 shows promising safety and efficacy, with no ...

PSMA PET imaging shows a 35% positivity rate in prostate cancer patients with PSA levels below 0.5 ng/mL post-radical prostatectomy. Factors linked to suspicious PSMA activity include prior ...

The MULTI-MIBI study demonstrated feasibility in recruiting patients for Tc-sestaMIBI SPECT/CT trials for T1 renal tumors, enrolling 50 patients over 15 months. Tc-sestaMIBI SPECT/CT showed a ...

Standardized imaging protocols and interpretation criteria are essential for consistent PSMA imaging results across clinical settings. Robust data on the impact of PSMA imaging on patient outcomes is ...

Posluma, a new PSMA-based tracer, will improve patient assessment for PSMA-based therapies like Lutetium-based theranostics. Dosimetry integration will enhance precision in identifying lesions and ...

Bone scans have been the standard for staging metastatic prostate cancer due to their ability to detect bone metastases indirectly. PSMA-PET offers superior specificity and accuracy compared to bone ...

Leslie M. Rickey is the first woman in Yale's Department of Urology to achieve full professor status, highlighting her expertise in female pelvic medicine and urogynecology. Women face significant ...

Germline genetic testing for prostate cancer has increased, especially after the 2018 NCCN guideline expansion. Urologists are ordering more tests, particularly for younger patients and those without ...